{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:42:38Z","timestamp":1761896558705,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clml.2017.05.001","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T23:46:51Z","timestamp":1494373611000},"page":"354-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Peripheral T-Cell Lymphoma in Community Settings"],"prefix":"10.1016","volume":"17","author":[{"given":"Tatyana","family":"Feldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M.","family":"Farber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Connors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhakshila","family":"Paramanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhi","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart L.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.05.001_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminhematol.2013.11.001","article-title":"The changing landscape of peripheral T-cell lymphoma in the era of novel therapies","volume":"51","author":"Karlin","year":"2014","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2017.05.001_bib2","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2012.48.3883","article-title":"Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve","volume":"31","author":"Lunning","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.05.001_bib3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.05.001_bib4","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-10-1214","article-title":"Folotyn (pralatrexate injection) for the\u00a0treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S.\u00a0Food and Drug Administration drug approval summary","volume":"16","author":"Malik","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.05.001_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.blre.2007.03.001","article-title":"Peripheral T-cell lymphomas","volume":"21","author":"Savage","year":"2007","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2017.05.001_bib6","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.05.001_bib7","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.05.001_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.05.001_bib9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/13696998.2016.1187622","article-title":"Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data","volume":"19","author":"Burudpakdee","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.clml.2017.05.001_bib10","first-page":"446","article-title":"Administration costs of intravenous chemotherapy in treating peripheral T-cell lymphoma","volume":"17","author":"Kruse","year":"2014","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clml.2017.05.001_bib11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.critrevonc.2015.12.016","article-title":"Panoptic clinical review of the current and future treatment of relapsed\/refractory T-cell lymphomas: peripheral T-cell lymphomas","volume":"99","author":"Zinzani","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2017.05.001_bib12","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.05.001_bib13","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.05.001_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.clml.2016.10.001","article-title":"Analysis of peripheral T-cell lymphoma diagnostic workup in the United States","volume":"17","author":"Hsi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2017.05.001_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00277-016-2891-8","article-title":"Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP\/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment","volume":"96","author":"Kitahara","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.05.001_bib16","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.05.001_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.beha.2013.04.008","article-title":"Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T\/NK-cell lymphomas","volume":"26","author":"Shustov","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2017.05.001_bib18","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.05.001_bib19","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2017.05.001_bib20","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"year":"2016","series-title":"ISOTODAX\u00ae (romidepsin) [package insert]","key":"10.1016\/j.clml.2017.05.001_bib21"},{"key":"10.1016\/j.clml.2017.05.001_bib22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"year":"2016","series-title":"BELEODAQ\u00ae (belinostat) [package insert]","key":"10.1016\/j.clml.2017.05.001_bib23"},{"key":"10.1016\/j.clml.2017.05.001_bib24","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"year":"2016","series-title":"FOLOTYN\u00ae (pralatrexate) [package insert]","key":"10.1016\/j.clml.2017.05.001_bib25"},{"key":"10.1016\/j.clml.2017.05.001_bib26","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"year":"2016","series-title":"ADCETRIS\u00ae (brentuximab vedotin) [package insert]","key":"10.1016\/j.clml.2017.05.001_bib27"},{"key":"10.1016\/j.clml.2017.05.001_bib28","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.05.001_bib29","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral t-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.05.001_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.12488","article-title":"A\u00a0phase I\/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas","volume":"163","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.05.001_bib31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"year":"2015","series-title":"As Community Oncology Falls, Cancer Costs Rise","key":"10.1016\/j.clml.2017.05.001_bib32"},{"key":"10.1016\/j.clml.2017.05.001_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","article-title":"The biology and management of systemic anaplastic large cell lymphoma","volume":"126","author":"Hapgood","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.05.001_bib34","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.05.001_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.05.001_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12185-013-1465-y","article-title":"High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis","volume":"99","author":"Gui","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2017.05.001_bib37","unstructured":"NCCN Clinical Practice Guidelines in Oncology. T-cell Lymphomas. Version 2.2017."},{"issue":"suppl 4","key":"10.1016\/j.clml.2017.05.001_bib38","first-page":"164","article-title":"Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE), a new international treatment registry","volume":"22","author":"Foss","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.05.001_bib39","article-title":"Analysis of peripheral T-cell lymphoma (PTCL) subtype by race and geography using the Comprehensive Oncology Measures For Peripheral T-Cell Lymphoma Treatment (COMPLETE) dataset","volume":"122","author":"Carson","year":"2013","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501730085X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501730085X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:15Z","timestamp":1761870555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501730085X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S215226501730085X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.05.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Peripheral T-Cell Lymphoma in Community Settings","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}